Company Overview and News

 
Westpac rate change lifts ASX to higher week

2018-08-31 theage.com.au
The Australian sharemarket has broken free of a week of political turmoil, as the major banks lifted the benchmark index to a fresh highs this week.
0215 TPGTF TPPTY GEM TPM SDA HTA

 
Westpac rate change lifts ASX to higher week

2018-08-31 smh.com.au
The Australian sharemarket has broken free of a week of political turmoil, as the major banks lifted the benchmark index to a fresh highs this week.
0215 TPGTF TPPTY GEM TPM SDA HTA

2
ASX flat as banks wipe telco gains

2018-08-30 theage.com.au
A strong session from the telecommunications sector wasn't enough to lift the sharemarket to a fifth straight advance, as the banks traded turbulently on the back of Westpac's variable interest rate hike.
NCMGF NCM RIO RMYHY RIO HTA 0215 RTPPF RTNTF MS RMSYF TPPTY WTCHF TPM SDA NCMGY TPGTF RIO RHC

2
ASX flat as banks wipe telco gains

2018-08-30 smh.com.au
A strong session from the telecommunications sector wasn't enough to lift the sharemarket to a fifth straight advance, as the banks traded turbulently on the back of Westpac's variable interest rate hike.
NCMGF NCM RIO RMYHY RIO HTA 0215 RTPPF RTNTF MS RMSYF TPPTY WTCHF TPM SDA NCMGY TPGTF RIO RHC

1
Networks, business ambitions line up for Vodafone, TPG

2018-08-30 smh.com.au
The strength of the strategic rationale for the proposed "merger of equals’’ between Vodafone Hutchison Australia (VHA) and TPG Telecom was laid bare in the detail of its announcement, helping to explain why the telcos were able to put aside their individual ambitions and work through the daunting complexities to agree a deal.
0215 TPGTF VOD VOD VODPF TPPTY TPM HTA

1
Networks, business ambitions line up for Vodafone, TPG

2018-08-30 theage.com.au
The strength of the strategic rationale for the proposed "merger of equals’’ between Vodafone Hutchison Australia (VHA) and TPG Telecom was laid bare in the detail of its announcement, helping to explain why the telcos were able to put aside their individual ambitions and work through the daunting complexities to agree a deal.
0215 TPGTF VOD VOD VODPF TPPTY TPM HTA

1
TPG and Vodafone announce merger

2018-08-29 abc.net.au
TPG Telecom and Vodafone Hutchinson Australia (VHA) have confirmed they will combine in a "proposed merger of equals".
0215 TPGTF VOD VOD VODPF TPPTY TPM HTA

1
Australia's TPG Telecom eyes Vodafone deal, shares soar

2018-08-22 theedgemarkets
SYDNEY (Aug 22): Australia's TPG Telecom Ltd said on Wednesday it was looking into a merger deal with rival Vodafone, a move that could provide a faster and cheaper entry into the mobile network market while tempering competition in the cut-throat industry.
0215 TPGTF VOD VOD VODPF TPPTY TPM HTA

1
Vodafone Hutchison in discussions to merge with TPG Telecom

2018-08-22 livemint
Sydney: Vodafone Group Plc and CK Hutchison Holdings Ltd. are considering combining their unprofitable mobile-phone business in Australia with local broadband provider TPG Telecom Ltd. as intensifying competition forces rivals to consolidate.
VOD VOD TPPTY TPM CKHUY TTRAF TLSYY HTA 0215 TPGTF VODPF CKHUF TLS

 
Hutchison Telecommunications a leading ASX gainer on TPG merger discussions

2018-08-22 proactiveinvestors.com.au
Hutchison Telecommunications (Aus) Ltd (ASX:HTA) is a leading ASX gainer on news of potential merger discussions between Vodafone Hutchison Australia Pty Limited and TPG Telecom Limited (ASX:TPM).
0215 HUWHF TPGTF TPPTY TPM HTA

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...